|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et
al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009.
View Article : Google Scholar
|
|
2.
|
Eltawil KM, Renfrew PD and Molinari M:
Meta-analysis of phase III randomized trials of molecular targeted
therapies for advanced pancreatic cancer. HPB (Oxford). 14:260–268.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
4.
|
Bartel D: MicroRNAs: genomics, biogenesis,
mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Piepoli A, Tavano F, Copetti M, Mazza T,
Palumbo O, et al: MiRNA expression profiles identify drivers in
colorectal and pancreatic cancers. PLoS One. 7:e336632012.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Nikitina EG, Urazova LN and Stegny VN:
MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.
|
|
7.
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Li C, Hashimi SM, Good DA, Cao S, Duam W,
et al: Apoptosis and microRNA aberrations in cancer. Clin Exp
Pharmacol Physiol. 39:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, et al: EGFR and MET receptor tyrosine kinase-altered
microRNA expression induces tumorigenesis and gefitinib resistance
in lung cancers. Nat Med. 18:74–82. 2011.PubMed/NCBI
|
|
10.
|
Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, et
al: A miR-200b/200c/429-binding site polymorphism in the 3′
untranslated region of the AP-2α gene is associated with cisplatin
resistance. PLoS One. 6:e290432011.PubMed/NCBI
|
|
11.
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, et al: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Jiang J, Gusev Y, Aderca I, Mettler TA,
Nagorney DM, et al: Association of MicroRNA expression in
hepatocellular carcinomas with hepatitis infection, cirrhosis, and
patient survival. Clin Cancer Res. 14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Miko E, Czimmerer Z, Csánky E, Boros G,
Buslig J, et al: Differentially expressed microRNAs in small cell
lung cancer. Exp Lung Res. 35:646–664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lu YC, Chen YJ, Wang HM, Tsai CY, Chen WH,
et al: Oncogenic function and early detection potential of
miRNA-10b in oral cancer as identified by microRNA profiling.
Cancer Prev Res. 5:665–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen
XM and Gao HJ: Initial study of microRNA expression profiles of
colonic cancer without lymph node metastasis. J Dig Dis. 11:50–54.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Cao G, Huang B, Liu Z, Zhang J, Xu H, et
al: Intronic miR-301 feedback regulates its host gene, ska2, in
A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem
Biophys Res Commun. 396:978–982. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, et al: MicroRNA-301 mediates proliferation and invasion
in human breast cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Lu Z, Li Y, Takwi A, Li B, Zhang J, et al:
miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J.
30:57–67. 2011.
|
|
19.
|
Funamizu N, Okamoto A, Kamata Y, Misawa T,
Uwagawa T, et al: Is the resistance of gemcitabine for pancreatic
cancer settled only by overexpression of deoxycytidine kinase?
Oncol Rep. 23:471–475. 2010.PubMed/NCBI
|
|
20.
|
Yang A, Kaghad M, Wang Y, Gillett E,
Fleming MD, et al: p63, a p53 homolog at 3q27-29, encodes multiple
products with trans-activating, death-inducing, and
dominant-negative activities. Mol Cell. 2:305–316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Yang A, Schweitzer R, Sun D, Kaghad M,
Walker N, et al: p63 is essential for regenerative proliferation in
limb, craniofacial and epithelial development. Nature. 398:714–718.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Yuan M, Luong P, Hudson C, Gudmundsdottir
K and Basu S: c-Abl phosphorylation of ΔNp63α is critical for cell
viability. Cell Death Dis. 1:e162010.
|
|
23.
|
Helton ES, Zhang J and Chen X: The
proline-rich domain in p63 is necessary for the transcriptional and
apoptosis-inducing activities of TAp63. Oncogene. 27:2843–2850.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Gressner O, Schilling T, Lorenz K, Schulze
Schleithoff E, Koch A, et al: TAp63alpha induces apoptosis by
activating signaling via death receptors and mitochondria. EMBO J.
24:2458–2471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Guo X, Keyes WM, Papazoglu C, Zuber J, Li
W, et al: TAp63 induces senescence and suppresses tumorigenesis in
vivo. Nat Cell Biol. 11:1451–1457. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Chiang CT, Chu WK, Chow SE and Chen JK:
Overexpression of delta Np63 in a human nasopharyngeal carcinoma
cell line downregulates CKIs and enhances cell proliferation. J
Cell Physiol. 219:117–122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Schavolt KL and Pietenpol JA: p53 and
Delta Np63 alpha differentially bind and regulate target genes
involved in cell cycle arrest, DNA repair and apoptosis. Oncogene.
26:6125–6132. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Sen T, Sen N, Huang Y, Sinha D, Luo ZG, et
al: Tumor protein p63/nuclear factor κB feedback loop in regulation
of cell death. J Biol Chem. 286:43204–43213. 2011.PubMed/NCBI
|
|
29.
|
Wu J, Bergholz J, Lu J, Sonenshein GE and
Xiao ZX: TAp63 is a transcriptional target of NF-kappaB. J Cell
Biochem. 109:702–710. 2010.PubMed/NCBI
|
|
30.
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Chua HL, Bhat-Nakshatri P, Clare SE,
Morimiya A, Badve S and Nakshatri H: NF-kappaB represses E-cadherin
expression and enhances epithelial to mesenchymal transition of
mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2.
Oncogene. 26:711–724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Funamizu N, Kamata Y, Misawa T, Uwagawa T,
Lacy CR, et al: Hydroxyurea decreases gemcitabine resistance in
pancreatic carcinoma cells with highly expressed ribonucleotide
reductase. Pancreas. 41:107–113. 2010. View Article : Google Scholar
|
|
33.
|
Funamizu N, Lacy CR, Fujita K, Furukawa K,
Takeyuki M, et al: Tetrahydrouridine inhibits cell proliferation
through cell cycle regulation regardless of cytidine deaminase
expression levels. PLoS One. 7:e374242012. View Article : Google Scholar : PubMed/NCBI
|
